Table 1 Patient demographics and clinical data
Patient Characteristics | Study Population | IBD | JIA | Uveitis |
|---|---|---|---|---|
Patients, n | 97 | 73 | 16 | 8 |
Gender, female, n (%) | 43 (44) | 29 (40) | 10 (63) | 4 (50) |
Age, yr, median [range] | 16 [5,21] | 16 [5,21] | 13 [7,20] | 16 [6,21] |
Diagnosis, n (%) | ||||
 IBD | 73 (75) |  |  |  |
 JIA | 16 (17) |  |  |  |
 Uveitis | 8 (8) |  |  |  |
IFX Dosing, median [IQR] | ||||
 Dose, mg/kg | 8.4 [6.5,9.8] | 7.7 [6.2,9.4] | 9.7 [8.5,10.7]* | 10.5 [7.5,12.0]# |
 Interval, weeks | 6 [4,7] | 6 [4,8] | 4 [4,5]* | 4 [4,6]# |
Immunomodulator, n (%) | ||||
 MTX | 37 (38) | 19 (26) | 12 (75)* | 6 (75)# |
 AZA | 3 (3) | 3 (4) | 0 (0) | 0 (0) |
Inflammatory Markers, median [IQR] | ||||
 ESR, mm/hr | 9 [6,17.5] | 9 [7,17] | 7 [6,17] | 13 [7,22] |
 CRP, mg/dL | 0.5 [0.5,0.8] | 0.5 [0.5,0.8] | 0.5 [0.5,0.6] | 0.7 [0.6,0.8] |
 Albumin, g/dL | 4.3 [4.0,4.5] | 4.3 [4.0,4.5] | 4.3 [4.2,4.6] | 4.3 [4.0,4.6] |